There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Inspection Record
Bello Bio LLC — FDA 483 Findings
Inspectors Garrad R Poole · Emily S Mcgann · Laurissa S FlowersThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The eligibility of an HCT/P donor was not documented by a responsible person, based on results of donor screening and donor testing.
Procedures designed to assure that correct labels and labeling are used for drug products are not written.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic process.
Procedures describing the handling of all written and oral complaints regarding a drug product are not established.
There is no quality control unit.
Batch production and control records do not include complete information relating to the production and control of each batch.
After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.
Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components and drug product containers.
There is no written testing program designed to assess the stability characteristics of drug products.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Drug products are not quarantined before being released by the quality control unit.
Procedures were not designed to ensure compliance with the donor eligibility requirements.
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that components conform to appropriate standards of identity, strength, quality and purity.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Alkem Laboratories Limited2016-09-29 · US FDASimilar to finding 10 There is no written testing program designed to assess the stability characteristics of drug products.
- CP Pharmaceuticals2015-10-13 · US FDASimilar to finding 10 There is no written testing program designed to assess the stability characteristics of drug products.
- Hiers Enterprises, LLC dba Northwest Compounding Pharmacy2018-11-29 · US FDASimilar to finding 10 There is no written testing program designed to assess the stability characteristics of drug products.
- Promise Pharmacy, LLC2018-11-12 · US FDASimilar to finding 10 There is no written testing program designed to assess the stability characteristics of drug products.
- Maag Prescription Center LLC2018-09-28 · US FDASimilar to finding 10 There is no written testing program designed to assess the stability characteristics of drug products.
A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.